Aclarion (ACON) to Release Quarterly Earnings on Tuesday

Aclarion (NASDAQ:ACON) is expected to announce its Q4 2025 results before the market opens on Tuesday, April 14th. Analysts expect the company to announce earnings of ($2.79) per share and revenue of $0.0250 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 7:00 AM ET.

Aclarion (NASDAQ:ACON) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($2.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.60) by $1.59. Aclarion had a negative return on equity of 52.31% and a negative net margin of 9,517.11%.The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. On average, analysts expect Aclarion to post $-263 EPS for the current fiscal year and $-217 EPS for the next fiscal year.

Aclarion Stock Down 4.5%

Shares of ACON opened at $3.41 on Tuesday. Aclarion has a 12-month low of $2.34 and a 12-month high of $12.03. The firm has a market capitalization of $7.78 million, a PE ratio of -0.20 and a beta of 1.13. The stock’s fifty day simple moving average is $3.03 and its 200-day simple moving average is $5.32.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ACON shares. Wall Street Zen raised Aclarion from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.